Han Liang

Mr. Han Liang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
YSYuhong Song
Yuhong Song
FXFangrong Xie
Fangrong Xie
SMShuoyi Ma
Shuoyi Ma
GDGuanghui Deng
Guanghui Deng
YLYunjia Li
Yunjia Li
LGLei Gao
Lei Gao

Verified
Journal Article
Open access
PDF file
XLXiuyun Li
Xiuyun Li
CZChenglun Zhang
Chenglun Zhang
EWEnhui Wu
Enhui Wu
HLHan Liang
Han Liang
XDXiangliang Deng
Xiangliang Deng
ZSZhongfeng Shi
Zhongfeng Shi
Osthole (OST) is a simple coumarin derivative with pharmacological effects in many types of cancer cells. However, its role and its mechanism of action in breast cancer 4T1 cells remain unclear. In this study, we explored the effects and potential mechanisms of action of OST in 4T1 cells. The MTT, PI, and Annexin V-FITC/PI methods were used to evaluate the effects of OST-treated and untreated 4T1 cells on viability, cell cycle, and apoptosis, respectively. UPLC-Q-TOF/MS combined with multivariate data analysis was used to screen potential biomarkers relevant to the therapeutic mechanisms of OST. Additionally, mTOR, SREBP1, and FASN protein levels were detected using western blotting in OST-treated and untreated 4T1 cells. OST inhibited 4T1 cell proliferation, blocked the cells from remaining in S-phase, and induced apoptosis. In 4T1 cells, OST mainly affected the phospholipid biosynthesis, methyl histidine metabolism, pyrimidine metabolism, and β-oxidation of very long chain fatty acid pathways, suggesting that metabolic changes related to lipid metabolism-mediated signaling systems were the most influential pathways, possibly via inhibition of mTOR/SREBP1/FASN signaling. Our findings reveal biomarkers with potential therapeutic effects in breast cancer and provide insight into the therapeutic and metabolic mechanisms of OST in 4T1 cells.